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Rosuvastatin therapY I (MERCURY I) trial in which
3140 adults with, or at risk of, coronary heart disease ini-
tially received a ﬁxed daily dose of RSV 10mg, ATV 
10 or 20mg, PRA 40mg or SIM 20mg. After 8 weeks’
treatment, patients were randomised to remain on treat-
ment or to switch treatments as follows: from ATV 
10mg, SIM 20mg, PRA 40mg to RSV 10mg or from
ATV 20mg to RSV 10 or 20mg for a further 8 weeks. In
a decision-analysis model, it was assumed that patients
not achieving goal on an alternative statin after 8 weeks
would be switched to RSV. Costs for drug acquisition,
primary care physician visits, nurse visits and laboratory
tests were included where appropriate. Cost-effectiveness
was expressed as the cost per patient treated to LDL-C
goal over a 16-week period. RESULTS: Initiating and
maintaining patients on RSV was more cost-effective than
either 1) initiating and maintaining on another statin; 
or 2) switching from another statin to RSV 10mg. Com-
pared with continuing on ATV, PRA or SIM, switching
to RSV would treat more patients to goal at an incre-
mental cost of €17–117 per extra patient treated to goal.
CONCLUSIONS: Initiating and maintaining patients on
RSV were more cost-effective than switching from the
other statins to RSV. For patients intially receiving other
statins, switching to RSV treated more patients to goal at
relatively little additional total cost while drug costs were
equivalent or lower.
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Coronary stents (metal mesh tube) are routinely used with
coronary angioplasty for the treatment of ischaemic heart
disease. As many as 25% of patients need reinterventions
post conventional coronary stenting due to re-narrowing
of the treated artery. OBJECTIVE: The objective is to
assess the total 6-month cost and the incremental cost-
utility of the TAXUSTM stent (TAXUS), a paclitaxel-
eluting coronary stent system, compared to conventional
stents (CS). METHOD: A decision analytical model was
developed to assess the 6-month cost and the incremen-
tal cost-utility of TAXUS compared to CS. The study
takes a UK NHS perspective. Clinical event rates for the
TAXUS and CS were taken from TAXUS II clinical trial.
Utility values were sourced from the literature. Unit cost
data were based on UK published sources. RESULTS:
Expected costs at 6 months were £4154 for CS and £4386
for TAXUS in the treated population. Compared to CS
TAXUS was cost saving in diabetic patients (CS £4546
vs. TAXUS £4152), cost neutral in small vessels (CS
£4301 vs TAXUS £4342) and slightly cost additive in
long lesions (CS £4306 vs TAXUS £4425). Most of the
initial increase in procedure cost is offset due to savings
in fewer repeat procedures. The incremental cost-utility
of TAXUS compared to CS ranged from £32,381/ QALY
in the total population to £4,500/ QALY in patients with
small vessels and to £13,500/ QALY in patients with long
lesions. In diabetic patients TAXUS was the dominant
strategy. CONCLUSIONS: Most of the initial increase in
procedural costs with TAXUS is offset due to savings in
repeat procedures. In some high-risk patient groups such
as diabetics and those with small vessels TAXUS is cost
saving or cost neutral. In all patient groups, TAXUS is a
cost-effective new treatment modality for patients with
coronary artery disease.
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OBJECTIVES: The use of early coronary catheterization
and revascularization in unstable coronary artery disease
(UCAD) varies, which could have important conse-
quences for patients as well as long-term costs. The 
objective of this study was to estimate the long-term 
cost-effectiveness and cost-utility ratios of this strategy.
METHODS: We analysed data in the open randomized,
clinical FRISC II invasive trial, which consisted of total
2457 patients, with signs and symptoms of UCAD. We
prospectively recorded the patients’ use of health services
as well as productivity losses. Health states scores were
obtained within the trial ﬁve times during the 2-years
follow-up. Results were analysed in both a societal and 
a health care provider perspective. The uncertainty was
handled using the net-beneﬁt approach. RESULTS: There
was a signiﬁcant 1.74% absolute reduction in mortality
in the invasive compared to the non-invasive group at
two-years follow-up. The difference in mean total cost
was SEK 11,386 $1,467). This difference was not signif-
icant. The estimated cost per quality adjusted life year
(QALY) gained for the invasive strategy, based on within
trial results and projected life expectancy, was SEK
22,873 ($2,948). The estimated cost per life year gained
was SEK 57,651 ($7,429). If costs of added life years were
included the cost per quality adjusted life year was SEK
78,077 ($10,061). CONCLUSIONS: Invasive strategy in
patients with unstable angina or non-ST-segment eleva-
tion myocardial infarction, was in the long-term per-
spective shown to be cost-effective. The results were
consistent in all subgroups.
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OBJECTIVE: To estimate the cost-effectiveness of citico-
line in comparison to conventional therapy for the treat-
ment of patients with acute ischemic stroke. METHODS:
Decision tree analysis incorporating economic data and
results from alternative systematic reviews of effective-
ness. Data on effectiveness were obtained from a system-
atic review performed by the Cochrane Stroke Review
Group (CSRG) and a pooled analysis of primary data
from clinical trials sponsored by the Ferrer Group.
Resource use was obtained from a panel of experts based
in 5 Spanish hospitals. Unit costs were obtained from the
centres included in the study and from prices published
by the Spanish health care authorities. Two alternative
scenarios were considered: hospitalised patient and hos-
pitalised patient with ambulatory follow-up. Sensitivity
analysis of the key variables included was performed. The
time horizon for the study was 12 weeks. RESULTS: Even
in the most unfavourable scenario analysed, citicoline
proved to be an efﬁcient treatment option in patients with
acute ischemic stroke. Citicoline led to increases in the
proportion of patients without discapacity of between
5% and 10%, compared to conventional treatment.
Based on the efﬁcacy ﬁgures reported by the CSRG, the
cost per patient treated with citicoline was €3026.12
when only hospitalisation was taken into account, while
the equivalent cost per patient receiving placebo was
€3127.34. When the costs of ambulatory follow-up were
added, the cost per patient increased to €3663.50 in 
the citicoline group and €3795.90 in patients receiving
placebo. CONCLUSION: Citicoline is an effective and
efﬁcient treatment alternative in the management of
stroke patients, in all of the scenarios analysed.
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OBJECTIVES: Timely detection of renal artery stenosis
(RAS) is important as it may cause renovascular hyper-
tension and renal impairment. In the Renal Artery Diag-
nostic Imaging Study in Hypertension (RADISH), 402
patients suspected of having RAS were submitted to 
computed tomographic angiography (CTA), magnetic 
resonance angiography (MRA) and digital subtraction
angiography (DSA), in order to investigate the diagnostic
performance of CTA and MRA. Providing policy makers
and clinicians with information about the costs associated
with applying different diagnostic imaging strategies for
detecting RAS is important. Therefore, also a compara-
tive short-term cost analysis was performed. METHODS:
The analysis involved three diagnostic strategies: 1) direct
DSA; 2) CTA ± DSA, and 3) MRA ± DSA. Strategies 2
and 3 included DSA as the gold standard to conﬁrm the
diagnosis. After a negative CTA or MRA test result no
further tests were performed. The cost calculations were
performed from the societal perspective. Data were ana-
lyzed using a decision model, combining original patient
data and medical literature data. Short-term costs were
deﬁned as costs occurring during the ﬁrst year after treat-
ment, including the diagnostic work-up and revascular-
ization procedure. RESULTS: The strategy, whereby
patients are referred for DSA only in case of a positive
CTA test result was the least costly option (€2286), fol-
lowed by MRA ± DSA and direct DSA (€2598 and €3695,
respectively). CONCLUSIONS: Considered from the cost
perspective, CTA followed by DSA only in case of a pos-
itive test result is the strategy of choice. However, the cost
consequences of false negative test results were not con-
sidered since these effects generally reveal in the long
term. Also, health beneﬁts in terms of quality of life 
and life expectancy were not included in the analysis.
Therefore, a cost-effectiveness Markov model, including
short and long term costs and health effects, is currently
built.
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OBJECTIVES: In the Irbesartan in Diabetic Nephropa-
thy Trial (IDNT), treatment with irbesartan demonstrated
23% and 20% reductions in the combined endpoint 
of doubling of serum creatinine (DSC), end-stage renal
disease (ESRD) or death in patients with hypertension,
type 2 diabetes, and overt nephropathy compared to
amlodipine and control respectively. A simulation model
was developed to project long-term cost consequences of
the IDNT in Hungary. METHODS: A Markov model
simulated progression from nephropathy to DSC, ESRD,
and death in patients with hypertension, type 2 diabetes
and overt nephropathy. Treatment-speciﬁc probabilities
were derived from IDNT. Hungarian-speciﬁc ESRD-
related data were retrieved from local databases. Delay in
onset of ESRD, life expectancy and mean lifetime costs
were calculated for patients with baseline age 59 years.
Future costs were discounted at 5% per annum, and clin-
ical beneﬁts were discounted at 0% and 5% per annum.
Extensive sensitivity analyses were performed. RESULTS:
Onset of ESRD was delayed with irbesartan by 1.41 and
1.35 years versus amlodipine and control respectively.
